Method for treating or reducing efp

Abstract

To provide a method for treating or reducing edematous fibrosclerotic panniculopathy (EFP) of a patient.SOLUTION: The present invention relates to a method for treating or reducing EFP of a patient includes administering one or multiple low dose injections of collagenase to an EFP affected region. The present invention includes a method in which the dose of collagenase per injection is approximately 50 to approximately 200ABC units, and / or the concentration of collagenase is approximately 50 to approximately 2000ABC units / milliliter (ml).SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 61 / 549,863, filed October 21, 2011. The entire contents of the above referenced application are incorporated herein by reference. [Background technology]

[0002] Connective tissue fibrosis (EFP), commonly referred to as cellulite, manifests as a topographical change in the appearance of the skin and is a condition that affects approximately 90% of postpubertal females (Rawlings (2006), Int J Cosmetic Sci 2006;28:175-90; Khan et al. (2010), J Am Acad Dermatol 2010;62:361-70). EFP manifests as pitted skin, giving the skin the familiar orange peel appearance. Dermal septa, composed of collagenase, are thought to play a causative role in the formation of the pits.

[0003] Collagenase, an enzyme with the special ability to digest collagen, has been used in various collagen-mediated diseases, such as Dupuytren's contracture, Peyronie's disease, lipomas, and adhesive capsulitis. U.S. Patent No. 4,645,668 and U.S. Patent Publication No. 20070224184 also disclose specific uses of collagenase. The primary source of collagenase is the fermentation product of the bacterium Clostridium histolyticum. An injectable formulation containing Clostridium histolyticum collagenase I and collagenase II is sold under the trademark XIAFLEX® and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Dupuytren's contracture.

[0004] The present invention relates to a method for treating or reducing EFP, the method comprising administering to an area affected by EFP It involves one or more collagenase injections. Summary of the Invention

[0005] The present invention is based on the discovery that collagenase can be effectively reduced or treated by one or more low dose injections into the affected area. The amount of collagenase in a single injection can be as little as 5 ABC units, or 0.00029 mg (0.29 μg). The total dose of collagenase administered depends on the size of the treatment area and is therefore about 5 to about 5000 ABC units. The concentration of collagenase is about 50 to about 2000 ABC units per milliliter (ml). 10,000 ABC units is equivalent to 0.58 mg collagenase.

[0006] In one embodiment, the present invention relates to a method of treating or reducing EFP in a patient, the method comprising administering one or more subcutaneous injections of collagenase to an EFP-affected area of ​​the patient, wherein the collagenase dose per injection is about 5 to about 200 ABC units, and the multiple subcutaneous injections are administered at multiple injection sites. In a particular aspect, multiple subcutaneous injections are administered at multiple injection sites. In a further embodiment, the concentration of collagenase administered is about 50 to about 2000 ABC units per milliliter. In an additional particular embodiment, each collagenase injection is administered in a volume of about 0.5 ml or less. In a further aspect, the total dose of collagenase administered is about 5 to about 2000 ABC units.

[0007] In another embodiment, the present invention relates to a method of treating or reducing EFP in a patient, the method comprising administering one or more subcutaneous injections of collagenase into an EFP-affected area of ​​said patient, wherein the total dose of collagenase administered to the affected area is about 5 to about 5000 ABC units, and wherein the multiple injections are administered at multiple injection sites. In certain aspects, each injection is about 5 to about 200 ABC units. In some embodiments, the concentration of collagenase administered is about 50 to about 2000 ABC units per milliliter, and / or each collagenase injection is administered in a volume of about 0.5 ml or less.

[0008] In yet another embodiment, the invention is a method of treating or reducing EFP in a patient, the method comprising administering one or more subcutaneous injections of collagenase to an EFP-affected area of ​​said patient, wherein the dose of collagenase administered to the affected area per injection is about 5 to about 200 ABC Units and the concentration of collagenase administered to the affected area is about 50 to about 2000 ABC Units / milliliter.

[0009] In a further aspect, the present invention relates to a method of treating or reducing EFP in a patient, the method comprising administering one or more subcutaneous injections of collagenase to the EFP-affected area, wherein the concentration of collagenase administered to the affected area is about 50 to about 2000 ABC units / milliliter, and the volume of each injection of collagenase is about 0.5 ml or less.

[0010] In some embodiments, the dose of collagenase administered per injection is about 5 to about 100 ABC units, in further embodiments, the dose of collagenase administered per injection is about 5 to about 50 ABC units.

[0011] The collagenase may be from a bacterial source or from a recombinant form of collagenase. In some embodiments, the collagenase is purified from Clostridium histolyticum. In further embodiments, the collagenase comprises collagenase I and collagenase II. In further embodiments, the collagenase is collagenase I and collagenase II purified from Clostridium histolyticum, comprising collagenase I and collagenase II.

[0012] The foregoing and other objects, features, and advantages of the present invention will become apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings, in which like reference characters refer to the same parts throughout the different views, and in which the drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. [Brief description of the drawings]

[0013] [Figure 1] In the diagram showing the injection template, each dot within an octagon represents an injection site. The X within the circle represents the injection site relative to the "center well." The four corners are labeled as upper right (UR), lower right (LR), upper left (UL), and lower left (LL). [Diagram 2] FIG. 13 shows the buttocks and upper posterior thigh with template corner markings. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] A description of the preferred embodiments of the present invention follows. As discussed above, the present invention is based on the discovery that low dose injections of collagenase into EFP-affected areas are effective in dissolving collagen, thereby reducing or treating said EFP. The amount of collagenase injected per injection may be as little as 5 ABC units, or 0.00029 mg. The total dose of collagenase administered depends on the size of the treatment area and therefore ranges from about 5 to about 5000 ABC units, and / or the concentration of collagenase used in the methods of the present invention ranges from about 50 to about 2000 ABC units per milliliter (ml). The doses and concentrations of collagenase used in the methods of the present invention are substantially lower than the doses and concentrations of collagenase currently used and approved by the U.S. FDA for the treatment of Dupuytren's contracture.

[0015] The words "a" or "an" are intended to include one or more, unless otherwise specified.

[0016] "Treating" or "treatment" of EFP includes administering a composition or agent described herein to improve the appearance of skin previously affected by EFP and / or achieve an improved aesthetic outcome. For example, treating EFP may include reducing the visible severity of EFP or reducing the severity or number of visible skin pits.

[0017] The present invention includes a method of treating or reducing EFP in a patient, the method comprising administering one or more subcutaneous injections of collagenase to an EFP-affected area, the multiple injections being injected at multiple injection sites within the EFP-affected area, and the collagenase dose administered per injection is about 5 to about 200 ABC units. In further embodiments, the collagenase dose per injection is about 5 to about 100 ABC units, or about 5 to about 50 ABC units, or about 10 to about 100 ABC units, or about 10 to about 50 ABC units. In further embodiments, the total collagenase dose administered to the affected area is about 5 to about 5000 ABC units. The present invention also encompasses a method comprising administering collagenase to an EFP-affected area, where the concentration of collagenase administered to the affected area is about 50 to about 2000 ABC units / ml. Additionally, the invention encompasses methods of treating or reducing EFP in a patient in which multiple collagenase injections are administered to the EFP-affected area, with the collagenase dosage per injection ranging from about 5 to about 200 ABC Units.

[0018] The EFP affected area (also referred to herein as the "target area" or "treatment area") is typically an area of ​​skin on the thigh and / or buttocks characterized by one or more depressions. In some embodiments, the area of ​​EFP treated with one or more collagenase injections is an area of ​​the upper outer surface of the thigh, or an area of ​​the buttocks not including the gluteal sulcus. The target area treated with collagenase may also be an area of ​​the right or left buttock or right or left thigh with a photonumeric EFP severity scale (CSS) score of 10 or greater, representing moderate to severe EFP severity (Hexsel et al. (2009). A validated photonumeric EFP severity scale, JEADV 2009;23:523-52, the contents of which are expressly incorporated herein by reference). The CSS is a photographic quantification scale that examines five key morphologic features of EFP: (A) number of pits, (B) pit depth, (C) morphologic appearance of the skin surface, (D) skin looseness, laxity or sagging, and (E) a classification scale originally described by Numberger and Muller in J Dermatol Surg Oncol 1978;4(3):221-29 (Hexsel et al., 2009). Each of these features is rated on a 4-point scale ranging from a low of 0 to a high of 3. The scale ranges from 0 to 15.

[0019] The target area treated with one or more injections of EFP is usually an area of ​​skin characterized by one or more dimples that are visible when the patient is in an upright position. The geometric area of ​​the treatment area depends on the size of the EFP-affected area. Thus, for example, if the EFP-affected area includes one dimple, the geometric area of ​​the target area is about 1 cm 2 ~about 5cm 2 In a further embodiment, the EFP affected area comprises a plurality of depressions and is less than 1 cm 2 In one embodiment, the target area has a geometric area of ​​greater than about 1 cm 2 ~about 200cm 2The target area has a geometric area of ​​about 1 to about 15 cm. Of course, since the target area is usually the thigh or buttock area, the area may be, for example, generally rectangular in shape and about 1 to about 15 cm long and about 1 to about 10 cm wide. In a further example, the target area is about 6 to about 15 cm long and about 4 to about 10 cm wide. Those skilled in the art will also appreciate that the target area may be generally circular or any other geometric shape depending on the desired area for treatment. Optionally, the target area may be characterized by at least one dermal depression that is approximately centered in the area of ​​EFP to be treated, where the area of ​​EFP is treated with one or more injections. The collagenase injection sites may be numbered and spaced apart within the EFP affected area to allow for uniform distribution and efficacy of the injected collagenase. The number of collagenase injections will usually depend on the size of the area to be treated. In some embodiments, the number of injection sites is at least one or more. In other embodiments, the number of injection sites is at least about 3 or more. In other embodiments, the number of injection sites is at least about 5 or more. In still other embodiments, the number of injection sites is at least about 7 or more. In further embodiments, the number of injection sites is at least 10 or more.

[0020] The treatment area is a single depression area or is otherwise approximately 5 cm 2In one embodiment, where the treatment area is a geometric area of ​​less than 1 cm, there is only a single injection site and about 5 to about 200 ABC units of collagenase are injected. Optionally, the single injection may be made in the center of the depression. In an embodiment where the treatment area is larger, there are multiple injection sites and about 5 to about 200 ABC units of collagenase are administered per injection. Optionally, the multiple injections include at least one injection administered in the center of a depression. For example, the injection sites may be spaced about 1 to about 4 cm apart from one another. In yet other aspects, the injection sites may be spaced about 2 to about 3 cm apart from one another. For example, in certain embodiments, the EFP affected area measures about 8 cm wide and about 10 cm long, the number of collagenase injections administered is 10, and the distance between injection sites is about 2.5 cm. In certain aspects, an injection template (e.g., made of a thin transparent material) containing markings indicating the intended injection sites is placed over the target area, and one or more injections are administered at the sites indicated by the template.

[0021] The target area is treated with one or more simultaneous collagenase injections. As used herein, simultaneous injections are injections administered sequentially at the same time or within the same time period, i.e., during a single treatment session. As discussed above, the total collagenase dose administered to the EFP affected area is about 5 to about 5000 ABC units of collagenase. The total collagenase dose administered depends on the size of the treatment area. The total collagenase dose is the sum of the doses administered by one or more collagenase injections. In certain embodiments, each collagenase injection contains an equal dose of collagenase. For example, if the number of injections distributed over the treatment area is 10, each injection containing 200 ABC units of collagenase, the total collagenase dose administered to the target area will be 2000 ABC units. In a further example, if the number of injections distributed over the treatment area is 10, each injection containing 5 ABC units of collagenase, the total collagenase dose administered to the target area will be 50 ABC units. In a further example, if the number of injections distributed over the treatment area is 5, each injection being 5 ABC units of collagenase, then the total dose of collagenase administered to the target area will be 25 ABC units. If only a single injection is performed and the selected dose is 5 ABC units, then the total dose of collagenase administered will be 5 ABC units. The concentration of collagenase administered to the affected area is from about 50 ABC units / ml to about 2000 ABC units / ml. Collagenase can be administered in a volume of about 0.5 ml or less per injection. In another aspect, collagenase can be administered in a volume of about 0.1 ml to about 0.5 ml per injection. For example, the total volume of collagenase administered can be from about 0.1 ml (if a single injection site is used) to about 7 ml (for multiple injection sites), and can be more for treatment areas of larger dimensions. In one embodiment, the treatment area is about 80 cm 2 In this case, the total volume administered is about 1 to about 5 ml, calculated from a total of 10 injections of 0.1 ml to 0.5 ml.

[0022] Collagenase is an enzyme with the special ability to digest collagen. One commercial source of collagenase is from fermentation by Clostridium histolyticum. In certain embodiments, collagenase comprises a combination of purified Clostridium histolyticum collagenase I and collagenase II. Collagenase I and collagenase II are preferably present in a mass ratio of about 1:1. Collagenase AUX I has a single polypeptide chain of about 1000 amino acids with a molecular weight of 115 kDa. Collagenase AUX II has a single polypeptide chain of about 1000 amino acids with a molecular weight of 110 kDa. Crude collagenase from Clostridium histolyticum can be purified by a variety of methods known to those skilled in the art, such as, for example, heparin affinity chromatography, ammonium sulfate precipitation, hydroxylapatite chromatography, size exclusion chromatography, ion exchange chromatography, and metal chelation chromatography. Also, a method for purifying crude collagenase from Clostridium histolyticum is described in U.S. Patent No. 7,811,560, the contents of which are expressly incorporated herein by reference. As discussed above, an injectable formulation containing Clostridium histolyticum collagenase I and collagenase II is sold in the United States under the trademark XIAFLEX® and is approved by the U.S. FDA for the treatment of Dupuytren's contracture. For example, the collagenase may be a parenteral lyophilized product consisting of two collagenases in an approximately 1:1 mass ratio: collagenase I (AUX-I, Clostridium type I collagenase) and collagenase II (AUX-II; Clostridium type II collagenase). The collagenase preferably comprises collagenase I and collagenase II in an approximately 1:1 mass ratio and having a purity of at least about 95% by area measured by reversed-phase high performance liquid chromatography (e.g., as described in U.S. Patent No. 7,811,560).

[0023] Collagenase compositions of the invention can also be prepared by mixing a specific number of activity units or a specific mass of purified enzyme. Collagenase activity can be measured by the ability of the enzyme to hydrolyze synthetic peptide or collagen substrates. Those skilled in the art will recognize that enzyme assays other than those disclosed herein can be used to define and prepare functionally equivalent enzyme compositions.

[0024] It will be understood that the terms "collagenase I," "ABCI," "AUXI," "collagenase AUXI," and "collagenase ABCI" refer to the same thing and can be used interchangeably. Similarly, the terms "collagenase II," "ABCII," "AUXII," "collagenase AUXII," and "collagenase ABCII" refer to the same enzyme and can be used interchangeably.

[0025] In further specific embodiments, the collagenase administered by the methods described herein is a recombinant collagenase.

[0026] Collagenase is administered as a pharmaceutical composition comprising collagenase and a pharma- ceutically acceptable carrier or diluent. In some embodiments, the composition does not contain protease enzymes other than collagenase (other than small or trace amounts of proteolytic enzymes that may be present in collagenase purified from bacterial fermentation). In further embodiments, the pharmaceutical composition does not contain enzymes other than collagenase (other than small or trace amounts of enzymes that may be present in collagenase purified from bacterial fermentation). One of skill in the art will appreciate that collagenase from bacterial fermentation, even after purification, may contain small or trace amounts of impurities, including other enzymes, such as other protease enzymes. For example, small or trace amounts of impurities may be less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the collagenase composition. In some embodiments, small or trace amounts of impurities may be less than about 1%, 2%, 3%, 4%, or 5% area as measured by reverse-phase high performance liquid chromatography. In another aspect, the pharmaceutical composition consists essentially of collagenase and a pharma- ceutically acceptable carrier or diluent. As used herein, a pharmaceutical composition "consisting essentially of collagenase and a pharma- ceutically acceptable carrier or diluent" is intended to exclude from the pharmaceutical composition protease enzymes and hyaluronidase, other than the other low or trace amounts described above. In a further particular aspect, a composition "consisting essentially of collagenase" excludes enzymes other than collagenase from the composition. In yet another embodiment, the pharmaceutical composition consists essentially of collagenase and a pharma- ceutically acceptable salt thereof.

[0027] The method of treating or reducing EFP may further include pre-treatment of the target area with a local anesthetic.

[0028] In a further aspect, the invention relates to treating or reducing EFP in a patient, comprising administering one or more collagenase injections to an area affected by EFP, wherein the collagenase administered is in a dose of about 5 to about 200 ABC units, and optionally, further comprising a concentration of collagenase of about 50 to about 2000 ABC units / ml.In yet a further aspect, the invention relates to treating or reducing EFP in a patient, comprising administering multiple collagenase injections, wherein the collagenase administered is in a dose of about 5 to about 200 ABC units per injection, and optionally, further comprising a concentration of collagenase of about 50 to about 2000 ABC units / ml.

[0029] The pharma- ceutically acceptable carrier may be one or more liquid carriers or excipients suitable for injection. As used herein, the term "pharma- ceutically acceptable carrier or excipient" refers to a non-toxic, inert, liquid injectable, diluent, encapsulating material, or formulation auxiliary of any type. Some examples of materials that can act as pharma- ceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffers; and other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, flavoring agents, preservatives, and antioxidants may also be present in the composition, at the discretion of the formulator. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile, fixed oils are conveniently used as solvents or suspending agents. For this purpose, any bland, fixed oils, such as synthetic mono- or diglycerides, can be used. In addition, fatty acids, such as oleic acid, can be used to prepare injectable solutions.

[0030] Injectable formulations can be sterilized, for example, by filtration through a sterile filter or by the addition of a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable solvent before use. Sterile solutions can also be lyophilized for later use. In one embodiment, the pharmaceutical composition containing collagenase is an injectable lyophilized composition formulated with lactose. In one embodiment, 1 milligram of injectable collagenase is formulated with 1.9 mg of lactose. In another embodiment, 1 milligram of injectable collagenase preferably contains about 2800 SRC units and 51000 units as measured by potency assay using the synthetic substrate pzGPGGPA.

[0031] In another embodiment, the collagenase composition used in the methods of the invention is a lyophilized injectable composition formulated with sucrose, Tris at a pH level of about 8.0. For example, 1.0 mg of the active pharmaceutical ingredient of the invention is formulated with 60 mM sucrose, 10 mM Tris at a pH of about 8.0 (which is equivalent to 20.5 mg / mL sucrose and 1.21 mg / mL Tris in the formulation buffer). Typically, a calcium source, such as calcium chloride, is included in the formulation.

[0032] The present invention will be better understood in connection with the following examples, which are for illustrative purposes only and are not intended to limit the scope of the present invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art, and such changes and modifications can be made without departing from the spirit of the present invention and the scope of the appended claims.

[0033] Working Example Example 1: Efficacy of collagenase Clostridium histolyticum in dissolving skin collagen in Gottingen minipigs Collagenase Clostridium histolyticum (Auxilium Product Operation, Malvern, PA) is a parenteral lyophilized product composed of two collagenases in an approximately 1:1 mass ratio: collagenase I (AUX-I, clostridial type I collagenase) and collagenase II (AUX-II, clostridial type II collagenase). These collagenases are isolated and purified from the fermentation of Clostridium histolyticum. The reconstitution vehicle for the lyophilized product was saline (0.9% sodium chloride) containing 0.03% (2 mM) calcium chloride. The vehicle for dilution and preparation of the formulations described in more detail below was saline (0.9% sodium chloride for injection; Baxter Healthcare Corporation, Deerfield, IL) containing 10 mM (0.13%) TRIZMA® (Sigma Aldrich, Inc., St. Louis, MO), 60 mM (2.0%) sucrose (Sigma Aldrich, Inc., St. Louis, MO), and 2 mM calcium chloride (pH 8.0) (Aldrich Chemical Corporation, Allentown, PA). The pH of the dilution vehicle was adjusted to 8.0 using IN HC1 (hydrochloric acid). The dilution vehicle was mixed throughout the formulation, sampling, and dose administration procedures. The dilution vehicle was then sterilized using a 0.22 μm PVDF syringe filter, placed into a sterile vial, and capped with a septum. The dilution vehicle was prepared in a laminar flow hood using sterile glassware and utensils in an aseptic manner.

[0034] Dosage formulations were prepared with the concentrations of test article (collagenase Clostridium histolyticum) shown in the table below. [Table 1]

[0035] Dosing formulations were prepared on the day of dosing. Reconstitution vehicle was used to reconstitute the lyophilized product to obtain a 2.5 mg / mL stock test article solution. Dilution vehicle was used to dilute the stock test article solution to prepare the formulation used for dosing. Formulations were kept on wet ice prior to and during dosing. Formulations were prepared in a laminar flow hood using sterile glassware and utensils in an aseptic manner.

[0036] The Göttingen miniature pig was used as the test system for this study. This species and breeds are recognized as suitable for general toxicity studies and have been utilized as a biomedical research model in various disciplines. Pigs show many similarities to humans in cardiovascular anatomy and physiology, digestive physiology, and integumentary structure and function. Due to the similarity of skin anatomy and physiology between pigs and humans, pigs have become a standard model for plastic surgery, wound healing, and skin toxicity studies (Svendsen et al, (1998), Scandinavian Journal of Animal Science 1998, 25(supplement 1):27-30). Historically, pigs have been used for the toxicological evaluation of potential therapeutic agents.

[0037] Gottingen minipigs (four males and three females) were obtained in good health from Marshall BioResources, North Rose, NY. Animals were approximately 3-4 months of age at time of receipt. Each animal received one dose of a total of 12 treatments, for a total dose of approximately 0.43 mg collagenase Clostridium histolyticum per animal. Animals were approximately 4 months of age at time of dosing. Body weights ranged from 7185 g to 8646 g for males and 9333 g to 9633 g for females at time of dose administration. Test formulations were administered to anesthetized animals on study day 0 with a subcutaneous injection (bolus) of Telazol / Xylazine. The day before injection, hair in the designated area of ​​injection was clipped, if necessary. Six injections were administered along the right and left lateral trunk of each animal using appropriately sized syringes and needles (16-23 gauge). Animals were not dosed more than once at the same site. Each subcutaneous injection consisted of a different, randomly assigned treatment (combination of formulation concentration and dose volume). Injection sites were spaced far enough apart to prevent possible reactions from adjacent injection sites. The area immediately surrounding the test article deposition site was marked with a permanent marker and remarked as necessary. Individual injection sites were labeled. The route of administration of choice for this study was subcutaneous injection.

[0038] No drug-related histological effects were detected in adipocytes, nerves, adnexal structures (hair follicles, sweat glands, and sebaceous glands) or overlying epidermis. No consistent differences in collagen solubility were noted between sexes or between animals euthanized 24 or 48 hours post-dose, as assessed by estimated collagen solubility. Necropsy results at 24 and 48 hours post-dose are summarized by sex in the table below. At concentrations below 0.015 mg / mL, collagen solubility was approximately dose-responsive. At concentrations above 0.015 mg / mL, collagen solubility was approximately proportional to the volume administered. This was in contrast to changes with total dose or formulation concentration (e.g., Test Articles 7 and 8, where Test Article 7 represents the same total dose as Test Article 8 due to the administration of a lower concentration and a larger volume). [Table 2]

[0039] Collagenase Clostridium histolyticum administered as a single subcutaneous injection at concentrations ranging from 0.0015 to 0.15 mg / mL produced local swelling at the treated site at collagenase Clostridium histolyticum concentrations of 0.015 mg / mL or greater in this study, and also produced collagen lysis (the expected pharmacological effect of collagenase Clostridium histolyticum) at all doses, dose volumes, and formulation concentrations. The minimal effective dose in this study was 0.0003 mg protein, and the minimal effective concentration was 0.0015 mg / mL. At concentrations below 0.015 mg / mL, there was an overall clear dose-response relationship for collagen solubility. At concentrations 0.015 mg / mL and greater, effective collagen solubility was more related to dose volume than to total dose or formulation concentration.

[0040] Collagenolysis was always accompanied by several secondary changes. These included hemorrhage and / or acute inflammation, which were always present at all effective dose levels; necrosis of muscle fibers in the tarsus carnosus at concentrations ≥0.003 mg / mL (total dose ≥0.0006 mg protein); perivascular and intramural edema, angiogenesis / fibrosis, vascular necrosis, and / or thrombosis, which were sporadically present at concentrations ≥0.009 mg / mL (total dose ≥0.0018 mg protein); and sporadically present within the arterial wall at formulation concentrations ≥0.030 mg / mL (total dose ≥0.003 mg protein). No collagenase Clostridium histolyticum-mediated effects were observed on adipocytes, nerves, adnexal structures, or the overlying epidermis.

[0041] The results of this study showed some histologically detectable collagen lysis of the dermal septa at all collagenase Clostridium histolyticum dose concentrations. However, more areas of complete lysis of the dermal septa were observed at concentrations of 0.015 mg / mL and above. There were no collagenase Clostridium histolyticum-mediated effects on adipocytes, nerves, adnexal skin structures, or the overlying epidermis in this study. Local effects of collagenase Clostridium histolyticum at each concentration (bleeding and / or acute inflammation) were observed by gross and / or microscopic examination at necropsy. No consistent differences in collagen solubility were noted between sexes or between animals euthanized 24 or 48 hours after dosing, with regard to estimated collagen solubility.

[0042] Minipig studies have demonstrated that at concentrations effective for complete dissolution of the dermal barrier, dose- and volume-dependent collagen lysis occurs within a diameter of approximately 2.5 cm.

[0043] Example 2: Phase 1b Open-Label Dose Escalation and Pharmacokinetic Study for the Treatment of EFP The purpose of this test is to 2 Objective: To evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of collagenase Clostridium histolyticum EFP for the treatment of adult women at increasing total doses ranging from 0.0029 mg to 0.116 mg (50 to 2000 ABC units) and increasing concentrations ranging from 0.0029 mg / mL to 0.116 mg / mL (50 to 2000 ABC units / mL) in the range of 0.0029 mg / mL to 0.116 mg / mL.

[0044] Based on the findings discussed above with respect to the minipig study (Example 1), the injection template for the Phase 1 clinical trial is designed to allow for a distance of approximately 2.5 cm between injections. This distance is expected to allow for adequate distribution and action of collagenase Clostridium histolyticum within the 8 cm x 10 cm area of ​​the EFP without significant gaps or overlaps within the treatment area. To determine the optimal dose for EFP treatment (e.g., effective with minimal local adverse effects), dose selection was performed based on both clinical development and practice as well as data from the minipig study, and after consideration of the favorable safety profile of collagenase Clostridium histolyticum to date. As a result, a starting dose of 0.0029 mg administered at a concentration of 0.0029 mg / mL within the 8 cm x 10 cm target EFP area by ten separate 0.00029 mg doses is proposed for the Phase 1 study.

[0045] This study is a Phase lb, open-label, dose-escalation and pharmacokinetic study. During the screening visit, while the subject remains upright, the investigator or a qualified designee will inspect the left and right buttocks and left and right thighs and select a quadrant with a Photo-Centric EFP Severity Scale (CSS) score of 10 or greater (Hexsel et al., 2009) representing moderate to severe EFP severity. The investigator or a qualified designee will identify an EFP area within the selection quadrant suitable for treatment (i.e., an area within the lateral superior aspect of the thigh or buttock that does not include the gluteal sulcus) that is at least 8 cm x 10 cm (i.e., the target EFP area). The target EFP area must be visually determinable while the subject is upright, without any manipulation such as pinching the skin or muscular contraction. Each subject will be screened for study eligibility within 21 days prior to injection of study drug on Day 1.

[0046] In this study, 63 subjects will receive 10 simultaneous equal-volume collagenase Clostridium histolyticum injections each in the target EFP area. After completion of study eligibility screening, subjects will be sequentially assigned to cohorts 1, 2, 3, and 4 (Table 3). The first 9 subjects will be assigned to cohort 1 (1 mL total volume / target EFP area). For each of the remaining cohorts 2-4, the first 9 subjects in each cohort will be assigned to 5 mL total volume / target EFP area, followed by the next 9 subjects to 1 mL total volume / target EFP area. Dosing will begin with cohort 1. Dosing in cohorts 2 and 3 will not begin until the safety evaluation of cohort 1 subjects has been completed by the Safety Monitoring Committee (SMC). Dosing in cohort 4 will not begin until the safety evaluation of cohorts 2 and 3 subjects has been completed by the SMC.

[0047] The suggested doses for treatment of an 8 cm x 10 cm EFP area are 0.1% (0.0029 mg / mL) to 5% (0.116 mg / mL) of the concentrations used in licensed products for Dupuytren's contracture and 0.5% (0.0029 mg) to 20% (0.116 mg) of the dose used in a single injection for Dupuytren's contracture. [Table 3]

[0048] The components of Collagenase Clostridium histolyticum are mixed collagenase AUX-I and AUX-II, 10 mM Tris, 60 mM sucrose. The components of Collagenase Clostridium histolyticum Sterile Diluent A for Reconstitution are 0.03% (2 mM) calcium chloride (CaCl) in 0.9% (154 mM) sodium chloride (NaCL) solution, pH 6.0-7.0, supplied in 3.0 mL / vial as a final sterilization solution. The components of Sterile Collagenase Clostridium histolyticum Buffered Sterile Diluent B for Further Dilution are 0.12% (10 mM) tromethamine (Tris) in 0.03% (2 mM) calcium chloride and 0.9% (154 mM) sodium chloride, pH 8.0 chloride, supplied in 3.0 mL / vial as a final sterilization solution. After reconstitution with Diluent A and further dilution with Diluent B, the A4500 solution may be held at room temperature (20°-25°C / 68°-77°F) up to 1 hour prior to administration or refrigerated at 2°-8°C (36°-46°F) up to 4 hours prior to administration.

[0049] An injection template is made of a thin transparent material. The 8cmx10cm injection template is pre-printed with the line diagram and injection sites shown in Figure 1. Each black dot within the octagon indicates an injection site. The circled "X" represents an injection site for the central depression (i.e., the area of ​​the deepest depression in the target area (Figure 1)). Each black dot (including the central depression and the four corner sites) is cut out to allow the investigator to mark the target EFP area as needed. Each dot within the octagon in Figure 1 represents an injection site. The X within the circle represents an injection site relative to the "central depression." The four corners are labeled upper right (UR), lower right (LR), upper left (UL), and lower left (LL).

[0050] During the screening visit, with the subject standing, the investigator or qualified designee will examine the left and right buttocks and the left and right upper posterior thighs to select the quadrants with moderate (CSS score ≥ 10) for severe EFP. The investigator or qualified designee will identify an EFP area within the selection quadrants (referred to as the target EFP area in this example) suitable for treatment (e.g., within the upper posterior thigh or buttocks, not including the gluteal sulcus) of at least 8 cm x 10 cm. The target EFP area should also be visually identifiable while the subject is standing without any manipulation (e.g., pinching the skin or contracting muscles).

[0051] The investigator then places the injection template over the target EFP area (with the subject still in an upright position) with the circled "X" on the template superimposed over the center of the deepest depression (e.g., central depression) within the target area. Using a surgical marker, the investigator marks the location of the two corners of the template on the subject's skin. The investigator removes the template and records which two template corners were marked (e.g., upper right, lower right, upper left, lower left). Using a tape measure, the investigator measures the following: 1. Identify the midline of the upper thigh and buttock starting at the center of the popliteal fossa (Figure 2). 2. Identify a line perpendicular to the midline and through the first template corner mark (as shown by line BC in Figure 2). Measure the distance between points B and C (record the distance). 3. Measure the distance from point A to point B as shown in Figure 2 (record the distance). 4. Repeat steps 2 and 3 to measure the second template corner marks (points A, D, and E in Figure 2). Each recorded measurement is used to reposition an 8 cm x 10 cm target EFP area prior to injection and prior to each efficacy assessment time point.

[0052] On day 1 post-injection, sites will be identified, marked (as described above), photographed, and pre-injection efficacy assessments completed, and subjects will be positioned in a prone position on the examination table such that the entire 8cm x 10cm target EFP area with previously marked injection sites is visible and can be assessed by the investigator. The injection site area will be prepped with an appropriate disinfectant, such as alcohol.

[0053] Using a previously prepared 5 mL or 1 mL syringe (depending on cohort allocation) with a 30 gauge 1 / 4 inch needle, the investigator will administer a 0.5 mL or 0.1 mL dose of collagenase Clostridium histolyticum to each of the 10 injection sites. At each of the 10 sites, the study medication will be injected perpendicular to the subject's skin to a depth of 1 / 4 inch (approximately 7 mm).

[0054] The investigator will administer the study medication in a manner that ensures that each of the 10 sites receives a single 0.5 mL or 0.1 mL collagenase Clostridium histolyticum injection. After the 10th injection, the maximum allowable volume of study medication will have been administered (5 mL or 1 mL). Any fluid on the surface of the injection site after injection (indicative of extravasation) will be noted and the associated injection site will be recorded. Local massage or palpation should not be performed after injection of study medication.

[0055] The following primary endpoints will be assessed at 90 days: Investigator-assessed global aesthetic improvement scale for target EFP areas; Subject's overall aesthetic improvement scale rating of the target EFP area; and Responder analysis based on the proportion of subjects who achieved at least a 30% improvement from baseline in the standard deviation of surface roughness of the target EFP area based on 3-D digital photography

[0056] While the present invention has been shown and described in detail with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the appended claims.

[0057] This application also includes the following inventions. (1) 1. A method of treating or reducing connective tissue fibrosis (EFP) in a patient comprising administering at least one subcutaneous injection of collagenase to an EFP-affected area, wherein the dose of collagenase per injection is from about 5 to about 200 ABC units. (2) The method of (1), wherein multiple subcutaneous injections are administered at multiple injection sites. (3) The method according to (1), wherein the concentration of the collagenase administered is about 50 to about 2000 ABC units / milliliter. (4) The method of any of (1) to (3), wherein each collagenase injection is administered in a volume of about 0.5 ml or less. (5) The method according to any one of (1) to (4), wherein the total dose of collagenase administered is about 5 to about 2000 ABC units. (6) The method according to any one of (1) to (5), wherein the dose of collagenase per injection is about 5 to about 100 ABC units. (7) The method according to any one of (1) to (5), wherein the dose of collagenase per injection is about 5 to about 50 ABC units. (8) The method according to any one of (1) to (7), wherein the collagenase is purified from Clostridium histolyticum. (9) The method according to any one of (1) to (8), wherein the collagenase is a recombinant collagenase. (10) The method according to (8), wherein the collagenase purified from Clostridium histolyticum includes collagenase I and collagenase II. (11) The method according to (5), wherein the collagenase I and collagenase II are present in a mass ratio of 1:1. (12) The method according to any one of (1) to (5), wherein the collagenase is present in a pharmaceutical composition consisting essentially of collagenase and a pharma- ceutically acceptable carrier. (13) The method according to any one of (1) to (5), wherein the collagenase is present in a pharmaceutical composition comprising collagenase and a pharma- ceutically acceptable carrier. (14) The method according to any one of (1) to (5), wherein the method essentially consists of administering one or more subcutaneous injections of collagenase. (15) The method according to any one of (1) to (5), wherein the method comprises administering one or more subcutaneous injections of collagenase. (16) The method according to any one of (1) to (5), wherein at least two collagenase injections are administered to two injection sites within the affected area. (17) The method of (16), wherein at least five collagenase injections are administered at five injection sites within the affected area. (18) 18. The method of claim 17, wherein at least 10 collagenase injections are administered at 10 injection sites in the affected area. (19) The EFP lesion is approximately 1 cm 2 ~about 200cm 2 The method according to any one of (1) to (18), wherein the area is (20) The method according to any one of (1) to (5), wherein multiple subcutaneous collagenase injections are administered and the distance between injection sites is at least about 1 to about 4 cm. (twenty one) The method according to (20), wherein the distance between the injection sites is about 2 to about 3 cm. (twenty two) The method of (19), wherein the EFP affected area has a length of about 10 cm and a width of about 8 cm. (twenty three) The method according to (22), wherein there is a distance of about 2.5 cm between the injection sites. (twenty four) The method according to any one of (1) to (5), wherein each injection has a volume of about 0.5 ml. (twenty five) The method according to any one of (1) to (5), wherein each injection has a volume of about 0.1 ml. (26) 1. A method of treating or reducing EFP in a patient comprising administering one or more subcutaneous injections of collagenase into an EFP-affected area, wherein the total dose of collagenase administered to said affected area is about 5 to about 5,000 ABC Units, each of said multiple injections is about 5 to about 200 ABC Units, and said multiple injections are administered at multiple injection sites. (27) The method of (26), wherein multiple subcutaneous injections of collagenase are administered at multiple injection sites. (28) The method according to any one of (26) and (27), wherein the concentration of the collagenase administered is about 50 to about 2000 ABC units / milliliter. (29) The method of any of (25) to (28), wherein each collagenase injection is administered in a volume of about 0.5 ml or less. (30) The method according to any one of (25) to (29), wherein the dose of collagenase per injection is about 5 to about 200 ABC units. (31) The method according to any one of (25) to (30), wherein the total dose of collagenase administered to the affected area is about 5 to about 2000 ABC units. (32) The method according to (31), wherein the total dose of collagenase administered to the affected area is about 5 to about 1000 ABC units. (33) The method according to any one of (26) to (32), wherein the collagenase is purified from Clostridium histolyticum. (34) The method according to any one of (26) to (32), wherein the collagenase is a recombinant collagenase. (35) The method according to (33), wherein the collagenase purified from Clostridium histolyticum includes collagenase I and collagenase II. (36) 36. The method of claim 35, wherein the collagenase I and collagenase II are present in a 1:1 mass ratio. (37) The method according to any one of (26) to (32), wherein at least two collagenase injections are administered to two injection sites within the affected area. (38) 37. The method of claim 37, wherein at least five collagenase injections are administered at five injection sites within the affected area. (39) 38. The method of claim 37, wherein at least 10 collagenase injections are administered at 10 injection sites within the affected area. (40) 1. A method of treating or reducing EFP in a patient comprising administering one or more subcutaneous injections of collagenase to an EFP-affected area, wherein the dose of collagenase administered to the affected area per injection is about 5 to about 200 ABC Units, the concentration of collagenase administered to the affected area is about 50 to 2000 ABC Units / milliliter, and the multiple injections are administered at multiple injection sites. (41) 40. The method of claim 40, wherein the multiple injections are administered at multiple injection sites. (42) The method of any of (40) and (41), wherein the volume of each administered collagenase injection is about 0.5 ml or less. (43) The method according to any one of (40) to (42), wherein each injection has a volume of about 0.2 ml or less.

Claims

1. A pharmaceutical composition used in a method for reducing connective tissue fibrosis (EFP) in a patient, The pharmaceutical composition contains collagenase I and collagenase II as the sole active ingredients in a mass ratio of approximately 1:1, wherein collagenase I and collagenase II have a purity of at least approximately 95% as measured by reverse-phase high-performance liquid chromatography, and collagenase I and collagenase II have a specific activity of 10,000 ABC units per 0.58 milligrams, and the method involves preparing the pharmaceutical composition and applying the pharmaceutical composition to the fibrotic (EFP) affected area multiple times A pharmaceutical composition comprising administration by simultaneous subcutaneous injection, wherein the dose of collagenase I and collagenase II per injection is approximately 0.00029 to approximately 0.0116 milligrams, the total dose of collagenase I and collagenase II administered by multiple simultaneous subcutaneous injections is approximately 0.00029 to approximately 0.116 milligrams, and the concentration of the administered collagenase I and collagenase II is approximately 0.0029 to approximately 0.116 milligrams / milliliter.

2. The pharmaceutical composition according to claim 1, wherein the fibrotic (EFP) affected area has a length of about 10 cm and a width of about 8 cm.

3. The pharmaceutical composition according to claim 1 or 2, wherein each subcutaneous injection is administered in a volume of approximately 0.5 ml or less.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the dose of collagenase I and collagenase II per subcutaneous injection is about 0.00029 to about 0.0058 milligrams.

5. The pharmaceutical composition according to any one of claims 1 to 3, wherein the dose of collagenase I and collagenase II per single subcutaneous injection is about 0.00029 to about 0.0029 milligrams.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the collagenase I and collagenase II are purified from Clostridium histolyticum.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the collagenase I and collagenase II are recombinant collagenases.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein at least two subcutaneous injections of the pharmaceutical composition are administered to two injection sites within the affected area.

9. The pharmaceutical composition according to claim 8, wherein at least five subcutaneous injections of the pharmaceutical composition are administered to five injection sites within the affected area.

10. The pharmaceutical composition according to claim 9, wherein at least 10 subcutaneous injections of the pharmaceutical composition are administered to 10 injection sites within the affected area.

11. The pharmaceutical composition according to claim 1, wherein the distance between the injection sites is about 1 cm to about 4 cm.

12. The pharmaceutical composition according to claim 11, wherein the distance between the injection sites is about 2 cm to about 3 cm.

13. The pharmaceutical composition according to claim 11, wherein the distance between the injection sites is approximately 2.5 cm.

14. The pharmaceutical composition according to any one of claims 1 to 3, wherein each subcutaneous injection is administered in a volume of approximately 0.5 ml.

15. The pharmaceutical composition according to any one of claims 1 to 3, wherein each subcutaneous injection is administered in a volume of approximately 0.1 ml.

Images